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osting by EAbstract Hepatitis C virus (HCV) causes serious infections in the liver which may lead to liver cir-
rhosis and hepatocellular carcinoma. Non structural 3 (NS3) protein is one of the most important
proteins of the virus which has protease and helicase activities. Protease activity has a crucial role in
the replication and persistence of the virus. Site directed mutation was carried out in the protease
region of one NS3 and another site directed mutation in the helicase region of another NS3. The
expression of both mutated NS3 was compared with wild NS3. Expression of the three different
NS3 types was conﬁrmed by in situ staining and western blotting using an anti-NS3 antibody
and correlated with a reduced antiviral response after treatment with interferon-a. Mutation anal-
ysis showed that the NS3 protease activity andnot the NS3 helicase was essential for the inhibition
of the interferon-a response.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) was identiﬁed as the causative agent
for most post-transfusion and sporadic non-A, non-B hepatitis
cases in 1989 (Ramadori and Meier, 2001). According toy. Production and hosting by
Saud University.
lsevierrecent estimates, about 170 million individuals worldwide are
infected and 3–4 million people are newly infected each year
(Cohen, 1999). It is a serious infection, affecting 1–2% of the
population in most developed countries. Around ninety per-
cent of HCV infections become chronic, up to 20% of these de-
velop into liver cirrhosis, and 1–5% of the cases leads to
hepatocellular carcinoma (Lanford et al., 2001). Although
treatment of this infection using interferon-a and ribavirin
has been effective in a minority of cases (about 40%), more
than 60% of patients show no response to treatment.
HCV is a single stranded RNA with positive polarity. The
HCV genome is approximately 9.6 Kb in length, shorter than
that of Flaviviruses and consists of a 50 NCR, a single open
reading frame (ORF) encoding a polyprotein of between
3010 and 3033 amino acids, which contains both the structural
proteins and non-structural proteins. The HCV ORF encodes
a single polyprotein that is 3008–3037 aa in length and is post-
translationally modiﬁed to produce at least ten different pro-
196 Z.M. Eisateins: core, envelope proteins E1 and E2, p7, and nonstructural
proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The NS3
protein is approximately 70 kDa in size and has been shown to
possess several important features for HCV replication and
host cell interactions. This protein has protease activity in
the N-terminal one third of the protein which is necessary
for the cleavage of certain regions of the HCV polyprotein
(Grakoui et al., 1993), helicase and NTPase activities in the
C-terminal two thirds (Kanai et al., 1995; Satoh et al., 2000).
The catalytic domain of the NS3 protease has been mapped
to the amino-terminal 181 amino acid (amino acids 1027–1207
of the polyprotein), with the minimal protease region being nar-
rowed down to amino acids 1059–1204. The N-terminal amino
acid region contains a characteristic serine protease catalytic
triad (His-1083; Asp-1107; Ser-1165). The importance of these
residues for polyprotein processing was later proven by several
groups who showed that substitutions affecting these residues
abolished the cleavage at the NS3/4A, NS4A/B, NS4B/5A and
NS5A/B junctions but not at the other sites (Tomei et al.,
1993). Deletions from the C-terminus of the NS3 181 protease
domain completely destroy the enzymatic activity whereas re-
moval ofN-terminal sequence leads to a gradual loss of cleavage
activity at various sites. While normal processing patterns are
observed for NS3 proteinases that lack up to 14 residues at the
N-terminus, deletion of 22 amino acid residues drastically re-
duces the cleavage at the NS4A/B site and blocks processing at
the NS4B/5A junction, whereas cleavage at the NS5A/B site is
poorly affected (Bartenschlager et al., 1994).
To investigate the possible roles of HCV NS3 protease and
helicase activities in the inhibition of the mode of action of
interferon alpha (IFN-a), it was necessary to obtain NS3
mutants that were inactive for the protease or the helicase.
An NS3 expression construct (pcDA) which has mutations
that result in almost complete inactivation of the helicase-
ATPase was previously constructed in Dr. McGarvey’s Labo-
ratory (Errington et al., 1999) and was available for this work.2. Material and methods
2.1. Tissue culture materials and reagents
All tissue culture plasticwares were purchased from VWR. All
tissue culture reagents were purchased from Invitrogen: RPMI
1640 and media supplements (FCS, glutamine, geneticin,
penicillin and streptomycin). Cell lines were maintained in
DMEM growth media supplemented with 2 mM L-glutamine,
10% fetal calf serum (FCS), 100 international units/ml penicil-
lin and 100 lg/ml streptomycin.
2.2. Site-directed mutagenesis
A point mutation was introduced into the plasmid pcDNAS3
(Dr. Andrew Wardell, Department of Medicine, Imperial
College, London) using a QuickChange II Site-Directed
Mutagenesis kit from Stratagene and standard PCR. All reac-
tion buffers were provided with the kit. Five microliter of 10x
reaction buffer, 1 ll of dsDNA template, 1.25 ll of primer
S1165A (TTG AAA GGC TCC GCG GGG GGT CCG C),
1.25 ll of primer S1165A (GCG GAC CCC CCG CGG AGC
CTT TCA A), 1 ll of dNTP mix, and 40.5 ll of ddH2O. In
addition, 1 ll of 2.5 U/ll PfuUltra HF DNA polymerase wasadded to the sample. The sample was placed in a PCR cycler.
Following temperature cycling the reactions were placed on ice
for 2 min to cool the reactions to 37 C. Once the reaction had
cooled down, 1 ll of 10 U/ll Dpn I restriction enzyme was
added to the reaction. The reaction was mixed by pipetting
the solution up and down several times. The reaction mixtures
were centrifuged in a microcentrifuge for 1 minute and imme-
diately incubated at 37 C for 1 h to digest the non-mutated
supercoiled parental dsDNA.
FiftymicroliterofXL1-Blue supercompetent cells (providedwith
the kit) were gently thawed and transformed with 1 ll of the Dpn I
restricted sample for 30 min on ice. The cells were heat-shocked
for 45 s at 42 C and then placed on ice for 2 min. NZY+ (0.5 ml)
was added to the transformation reaction which was incubated for
1 h at 37 C with vigorous shaking. Hundred microliter, 150 ll
and 250 ll were plated onto LB-Amp agar plates and incubated
overnight at 37 C. Single colonies were picked to inoculate 5 ml of
LB-amp and incubated overnight at 37 C with vigorous shaking.
The mutated DNA was puriﬁed using a Qiagen Miniprep kit and
sent for sequencing by using a primer for sequencing NS3 mutants
(50 CCC CGGTGT T) to conﬁrm the mutation.
2.3. Immunoﬂuorescent in situ staining
Glass cover slips were sterilised (dipped in alcohol and ﬂamed)
and placed in the bottom of the wells of Sterilin 6 well plates.
HCV RNA replicon cells were seeded in half of the wells while
the rest of the wells were seeded with Huh7 cells. The cells left
to grow up to 80% conﬂuence.
2.4. Western blot
Western blot analysis was performed on the total lysates from
negative and positive controls and siRNA-transfected S1179I
cells as described (Kapadia et al., 1999). The gels were trans-
ferred to Hybond-N membranes (Amersham Pharmacia),
blocked, and incubated with antibodies to NS3 followed by
incubation with a horseradish peroxidase-conjugated mouse
anti-rabbit antibody. The blots were developed with (Hyper-
ﬁlm ECL, Amersham Biosciences).
2.5. Interferon anti-viral assay
The standard antiviral assay used here is based on the fact that
encephalomyocarditis virus (EMCV) (Generously provided by
Dr. D. Watling from Cancer UK, London, UK) is sensitive to
the antiviral effects of interferon and EMCV can replicate in
the Huh7 cell line (Koev et al., 2002).
A 96 well plate was seeded with Huh7 cells which were al-
lowed to grow at a density of 1 · 104 cells per well. These cells
were then transfected with plasmids which expressed protease
mutant NS3 (pcDNS3-SA 3), helicase mutant NS3 (pcDA)
and wild-type NS3 as well as a negative control (pcDNA).
The wells were treated with interferon-a at different concentra-
tions (0, 0.3, 0.7, 1.5, 3.1, 6.3, 13.5, 25, 50, 100, 1000 U/ml)
(18 IE/IU, Roche). All the cells were then infected with
EMCV, except the virus negative control (C), for 1 h and then
left to grow overnight. The cells were then stained with ethyl-
ene violet (Fig. 3a). The cells in the 96 well plate were then
counted by using a cell reader at absorbance 540 nm
(Fig. 3b). The absence of staining at pcDNA (at concentration
of 100 U/ml IFN-a) and wild-type NS3-1B (at concentration
Effect of protease and helicase mutations on HCV NS3 activity 197of 13.5 U/ml IFN-a) was probably due to an experimental
error.
The medium was removed and the cells were incubated with
EMCV at 1 pfu/cell (in 2% RPMI 1640). After 1 h the medium
was removed and replaced with supplemented RPMI 1640.
Approximately 16–24 h later, cell viability was determined by
staining with crystal violet and the absorbance was measured
at 570 nm using a plate reader (Dynatech Immunoassay
System). Assays were usually performed in duplicate, data
were plotted and a dose-response curve was constructed.
3. Results
3.1. Site-directed mutagenesis of NS3 protease
Primers were designed that would introduce mutations into
amino acids that were known to be essential for protease activ-
ity (i.e. the catalytic triad) and studies have shown that muta-Table 1 Position of mutated nucleotides in sequencing data
and additional mutation was detected in one of the clones.
Clone Nucleotide position of
the desired mutant
Additional mutations
pcDNS3-SA2 1165 1158: G to A
pcDNS3-SA3 1165 None detected
Figure 1 Expression of NS3 protease and helicase mutants. NS3-7 an
(Wild NS3), (B) pcDA (helicase mutant), (C) pcDNS3-SA 3 (proteasetions at this position result in the loss of protease activity
(Grakoui et al., 1993).
Site-directed mutagenesis using these primers was per-
formed, using a QuickChange II Site-Directed Mutagenesis
Kit. DNA isolated from almost all E. coli strains is dam meth-
ylated and therefore susceptible to restriction enzyme Dpn I
digestion. Therefore after site-directed mutagenesis, the DNA
was digested with Dpn I and transformed into XL 1-Blue
supercompetent cells. The Dpn I cleaved the parental DNA
template and consequently selected the newly synthesized
DNA that contains that target mutation. The transformed
bacteria were plated onto an agar plate containing ampicillin.
Six colonies were picked and grown in 5 ml of LB media over-
night. The plasmid DNA was then puriﬁed from the cultures
using a Qiagen Miniprep Kit. The puriﬁed plasmids DNA
were run on a 1% agarose gel.
A single nucleotide change corresponding to the target site,
nucleotide 1165 was observed in the DNA sequence of two of
these plasmid clones: pcDNS3-SA2 and pcDNS3-SA3. The
mutation resulted in the change of serine (TCG) at position
1165 to alanine (GCG) and was thus called S1165A (Table 1).
To conﬁrm that the correct mutation had been introduced,
the clones were sequenced. The sequence data conﬁrmed that a
point mutation was introduced, a T to a G, at the correct posi-
tion in pcDNS3-SA clones 2 and 3. No other changes in the
coding sequence of NS3 were found with pcDNS3-SA3, how-
ever, an additional (unpredicted) mutation was found with
pcDNS3-SA2 (Table 1). Consequently pcDNS3-SA3 was usedtibody was used to stain Huh7 cells transfected with (A) pcDNS3
mutant), and (D) pcDNA.
198 Z.M. Eisaas a protease knock-out expression construct in subsequent
experiments.
3.2. Expression of NS3 protease and helicase mutations: in situ
staining
To investigate the effects of the site-directed mutagenesis of the
protease and helicase regions of HCV-1a in the replication of
the virus and their effect on the cell in the presence of IFN-
a, the expression of wild type NS3, the protease mutant NS3
(pcDNS3-SA3) and the helicase mutant (pcDA) were com-
pared. In situ staining for NS3 was carried out using the
NS3-7 antibody and visualized by a ﬂuorescent microscope.
Cells which had been transfected with constructs corre-
sponding to all the different types of NS3 (wild-type, protease1 2 3 4 5 
70kDa
Figure 2 Expression of NS3 protease and helicase mutants by
Western blotting using NS3-7 antibody: (1) pcDNA, (2) wild-type
NS3 1b, (3) wild-type NS3 1a, (4) helicase mutant NS3 (pcDA)
and (5) protease mutant NS3 pcDNS3-SA3.
C 0 .3 .7 1.5 3.1 6.3 13.5 25 50 100 1000
pcDNA
Prot mut
Hel mut
wt NS3 1a
Wt NS3 1b
Wt NS3 1b
Effects of HCV on Alpha Interferon Responses
Figure 3a Effects of HCV NS3 on the presence of EMCV
infected Huh7 cells to a-interferon treatment.mutant and helicase mutant) were stained with NS3-7 showing
that mutations in NS3 do not affect its expression in Huh7
cells. The negative control which contains pcDNA does not
show any staining (Fig. 1).
Additional evidence that the mutations in the protease and
helicase regions result in the same level of NS3 expression as
with wild type NS3, Western blot analysis of Huh7 cells trans-
fected with these constructs was carried out. It was clearly
shown that NS3 was present at similar levels in the cells which
expressed the protease mutant (pcDNS3-SA3), the helicase
mutant (pcDA), and both wild-type NS3 1a and 1b by the
presence of a 70 kDa band. No band was seen for the negative
control, pcDNA (Fig. 2).
3.3. Effect of different HCV NS3 mutants on IFN-a responses
The results showed that cells transfected with pcDNA 3.1 had
a similar resistance proﬁle to EMCV infection when treated
with increasing concentration of IFN-a, compared to the cells
transfected with the protease mutant (pcDNS3-SA3). By con-
trast, cells transfected with pcDNS3 (wild-type NS3) had a
similar resistance proﬁle compared to those of EMCV infec-
tion when treated with increasing concentration of IFN-a as
the cells transfected with the helicase mutant (pcDA). The cells
transfected with pcDNA or the protease mutant have more
resistance to EMCV (less cytopathic effect) than those trans-
fected with the helicase mutant or wild-type NS3 which have
less resistance to EMCV and more cytopathic effects. The re-
sults also showed that as IFN-a concentration increased, fewer
cells died. However, increasing IFN-a concentration in the
cells transfected with wild-type NS3 (pcDNS3) or helicase
mutation showed more death in those cells (Fig. 3a).4. Discussion
To try to determine if either the protease or helicase functions
of NS3 were essential for the activity of NS3 in inhibiting
IFN-a, mutants which were non-functional for one of these
enzymatic activities were obtained. A non-functional helicase
mutant was available in Dr. McGarvey’s Laboratory (Errington
et al., 1999), however, it was necessary to make a non-
functional NS3 protease mutant expression construct. Before
carrying out mutagenesis of the protease domain, it was impor-
tant to choose an amino acid which was known to be critical for
the function of the protease activity. The three amino acids that
constitute the catalytic triad (His-57, Asp-81, Ser-139) have
been shown to be crucial for the protease activity and are highly
conserved among different HCV strains (Grakoui et al., 1993).
Consequently site-directed mutagenesis was carried out to alter
the serine residue (Ser-139) of the catalytic triad to alanine and
subsequent DNA sequence analysis conﬁrmed that the site di-
rected mutagenesis had been successful, without any additional
mutations being introduced into this construct.
The plasmid constructs that expressed the helicase and pro-
tease mutants as well as wild-type NS3, as a positive control,
and pcDNA, as a negative control, were used to transfect
Huh7 cells. As expected, in situ staining of the transfected cells
with anti-NS3 antibody was positive for the wild-type NS3
while pcDNA showed no staining. Western blotting also
showed bands of 70kD with the NS3-1a and NS3-1b positive
controls as well as the helicase and protease mutants whereas
00.1
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0.4
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0.7
A
54
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Protease Mutant
Helicase Mutant
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Figure 3b Effects of HCV NS3 on alpha interferon responses. The absorbance readings of the stained cells (shown in 5.3A) were
measured at 540 nm and presented in graphic form.
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detection of similar levels of the helicase and protease mutants
compared to wild-type NS3 using in situ staining and Western
blotting means that these mutations have no effect on the
expression of NS3 in Huh7 cells (Gorbalenya et al., 1989;
Koonin, 1991).
Having established that the NS3 constructs could express
the different NS3 proteins in the transfection system it was
then possible to examine their effects on altering the responses
of the cells to IFN-a treatment. The EMCV interferon sensitiv-
ity assay was used to compare the effects of the expression of
the protease and helicase mutants to the wild-type NS3 and
pcDNA transfected Huh7 cells. With pcDNA more cells were
protected from EMCV as the concentration of IFN-a was in-
creased compared to wild-type NS3-1a and 1b expressing cells,
where more cells were killed by EMCV due to the inhibition of
IFN-a by NS3. With the NS3 protease mutant, little sign of
IFN-a inhibition was observed as the pattern of EMCV infec-
tion was similar to that of the pcDNA 3.1 transfected cells.
However, the mutation in the NS3 helicase did not affect the
ability of NS3 to inhibit IFN-a activity since the pattern of
NS3 helicase mutant expressing cells killed by the EMCV
was very similar to those of 1a and 1b wild-type NS3.
These results show that the NS3 protease domain is crucial
in the inhibition of IFN-a activity whereas an active helicase
domain is not necessary for this inhibition. The likely reason
for this is that the protease targets one or more cellular pro-
teins, which results in the inhibition of IFN-a activity. These
ﬁndings are consistent with recently published results, which
showed that NS3/4A protease activity inhibited the phosphor-
ylation of IRF-3, a key transcriptional regulator of the IFN-a
response (Wardell et al., 1999; Foy et al., 2003; Breiman et al.,
2005). NS3/4A protease has also been shown to be able to dis-
rupt retinoic acid-inducible gene I (RIG-I) signaling which
interrupts an IFN-a signaling pathway (Foy et al., 2005). In
addition, the NS3/NS4A serine protease caused proteolysis
of a Toll-IL-1 receptor domain-containing an adaptor protein
linking TLR3 to a kinase responsible for activating IRF-3 (Li
et al., 2005). Therefore, there appears to be a number of cellu-lar targets for NS3/NS4A protease which results in the inhibi-
tion of IFN-a signaling. In the present study NS3 on its own
(i.e. without NS4A) was shown to be capable of inhibiting
IFN-a activity. It will be interesting to see if NS3 targets the
same substrates as NS3/NS4A.References
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